GlassScriptPhysician profile
Ikenna Nwamba
NPI 1356872832
$1,405.70
in general payments reported to CMS, 2019-2025
17 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2022: $232 · 2023: $285 · 2024: $346 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $311.60 | 2022-2023 | Hetlioz, Fanapt |
| Paratek Pharmaceuticals, INC. | $178.53 | 2024-2025 | Nuzyra |
| Glaxosmithkline, LLC. | $147.59 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $121.84 | 2025 | Austedo Xr |
| Novo Nordisk INC | $111.44 | 2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $105.92 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $42.37 | 2023-2025 | Zoryve, Seglentis |
| Abbott Laboratories | $42.29 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $40.35 | 2025 | Repatha, Otezla |
| Ani Pharmaceuticals, INC. | $33.07 | 2025 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $32.81 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $29.96 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.92 | 2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $22.78 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.50 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikenna Nwamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.